<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174328</url>
  </required_header>
  <id_info>
    <org_study_id>PrOvAS001</org_study_id>
    <nct_id>NCT02174328</nct_id>
  </id_info>
  <brief_title>Prevention of Preeclampsia With Aspirin in Recipients of Donated Oocytes.</brief_title>
  <acronym>PROVAS</acronym>
  <official_title>Prevention of Preeclampsia With Aspirin Administered From the Beginning of Pregnancy in Recipients of Donated Oocytes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigacion Sanitaria La Fe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigacion Sanitaria La Fe</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this trial is to study the occurrence of preeclampsia in recipients of
      donated oocytes receiving aspirin at an early stage during pregnancy and to compare the
      results with those obtained in patients receiving placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Various markers have been proposed for the early diagnosis of preeclampsia: determination of
      mean arterial pressure; presence of multiple risk factors of preeclampsia; biochemical,
      ultrasound, and angiogenic markers; uterine artery Doppler, etc. These are used to
      determinate which patients have an increased risk of developing preeclampsia during
      gestation, and therefore carry out closer monitoring of pregnancy in this population. In
      addition, these markers can also identify patients at increased risk of developing other
      problems such as IUGR or preterm labor.

      For nearly 30 years, there have been multiple studies trying to demonstrate that aspirin
      prevents the onset of preeclampsia with inconclusive results. However, recent studies in
      which aspirin was administered at an early stage (before 16 weeks of gestation) in patients
      at high risk of complications, have demonstrated a decrease in the incidence of this entity.
      Thus, administration of aspirin to patients at high risk (patients classified with a high
      risk of complications during pregnancy, based on markers mentioned above) seems to be useful
      in preventing onset of preeclampsia, IUGR and other complications, whenever it is
      administered at an early stage, as shown by several studies carried out so far.

      The incidence of preeclampsia, IUGR and other complications of pregnancy is increased in
      patients undergoing treatment for ovulation induction, being much higher in recipients of
      donated oocytes. It appears that this increase may be explained by immunological processes.
      The focus lies on the interaction between HLA-C fetal antigen with the maternal natural
      killer cells. We postulate, therefore, that the administration of aspirin in recipients of
      donated oocytes at an early stage of pregnancy, may also reduce the incidence of preeclampsia
      in this group of patients.

      Moreover, it has been observed that patients with preeclampsia exhibit lower levels of VEGF,
      PlGF and PAPP-A (factors involved in placental angiogenesis) and that this is accompanied by
      an increase in the sFlt1 (a potent PIGF and VEGF antagonist).
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Halted prematurely due to low recruitment rate.
  </why_stopped>
  <start_date type="Actual">May 21, 2014</start_date>
  <completion_date type="Anticipated">May 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of preeclampsia.</measure>
    <time_frame>Up to 42 weeks</time_frame>
    <description>The main objective is to study the occurrence of preeclampsia in recipients of donated oocytes receiving aspirin at an early stage during pregnancy, and to compare the results with those obtained in patients receiving placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other complications</measure>
    <time_frame>Up to 42 weeks</time_frame>
    <description>Determine the development of gestational hypertension, severe preeclampsia, IUGR, and preterm delivery in this group of patients.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Inflammatory mediators involved in angiogenesis.</measure>
    <time_frame>Up to 42 weeks</time_frame>
    <description>Another objective is to determine if aspirin, through blockade of cyclooxygenase-2, could act in addition to reducing the synthesis of thromboxane 2, altering or diminishing the formation of various inflammatory mediators involved in angiogenesis.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Pre-Eclampsia</condition>
  <arm_group>
    <arm_group_label>acetylsalicylic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive 1 tablet of acetylsalicylic acid (100 mg) orally daily from 5-10 weeks gestation until the end of gestation, about week 36</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will receive 1 tablet of placebo orally each day from 5-10 weeks gestation until the end of gestation, about week 36</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>Acetylsalicylic acid once a day until 36 week</description>
    <arm_group_label>acetylsalicylic acid</arm_group_label>
    <other_name>ADIRO 100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once a day until 36 week</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Not active drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years.

          -  Recipients of donated oocytes.

          -  Pregnant women.

          -  Single or twin gestations.

          -  Patients who accept the conditions of the study by signing the appropriate informed
             consent.

        Exclusion Criteria:

          -  Known allergy to acetylsalicylic acid .

          -  Personal history of peptic ulcer.

          -  Triplets.

          -  Use of prostaglandin inhibitors within 10 days prior to baseline.

          -  Personal history of chronic kidney, thyroid, liver or heart disease.

          -  Psychiatric or cognitive pathology that prevents understanding of the conditions of
             informed consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfredo Perales, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>La Fe University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Obstetrics Unit of La Fe University and Politechnic Hospital</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Ebrashy A, Ibrahim M, Marzook A, Yousef D. Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial. Croat Med J. 2005 Oct;46(5):826-31.</citation>
    <PMID>16158479</PMID>
  </reference>
  <reference>
    <citation>ACOG Committee on Practice Bulletins--Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002 Jan;99(1):159-67.</citation>
    <PMID>16175681</PMID>
  </reference>
  <reference>
    <citation>Akolekar R, de Cruz J, Foidart JM, Munaut C, Nicolaides KH. Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. Prenat Diagn. 2010 Mar;30(3):191-7. doi: 10.1002/pd.2433.</citation>
    <PMID>20101671</PMID>
  </reference>
  <reference>
    <citation>Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn. 2011 Jan;31(1):66-74. doi: 10.1002/pd.2660. Erratum in: Prenat Diagn. 2011 Aug;31(8):832.</citation>
    <PMID>21210481</PMID>
  </reference>
  <reference>
    <citation>Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2008 Nov;32(6):732-9. doi: 10.1002/uog.6244. Erratum in: Ultrasound Obstet Gynecol. 2009 Feb;33(2):249.</citation>
    <PMID>18956425</PMID>
  </reference>
  <reference>
    <citation>Audibert F, Boucoiran I, An N, Aleksandrov N, Delvin E, Bujold E, Rey E. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol. 2010 Oct;203(4):383.e1-8. doi: 10.1016/j.ajog.2010.06.014. Epub 2010 Aug 5.</citation>
    <PMID>20691410</PMID>
  </reference>
  <reference>
    <citation>Brosens I, Pijnenborg R, Vercruysse L, Romero R. The &quot;Great Obstetrical Syndromes&quot; are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011 Mar;204(3):193-201. doi: 10.1016/j.ajog.2010.08.009. Epub 2010 Nov 20. Review.</citation>
    <PMID>21094932</PMID>
  </reference>
  <reference>
    <citation>Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001;20(1):IX-XIV. Review.</citation>
    <PMID>12044323</PMID>
  </reference>
  <reference>
    <citation>Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguère Y. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010 Aug;116(2 Pt 1):402-14. doi: 10.1097/AOG.0b013e3181e9322a.</citation>
    <PMID>20664402</PMID>
  </reference>
  <reference>
    <citation>Imperiale TF, Petrulis AS. A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertensive disease. JAMA. 1991 Jul 10;266(2):260-4.</citation>
    <PMID>1829118</PMID>
  </reference>
  <reference>
    <citation>Keegan DA, Krey LC, Chang HC, Noyes N. Increased risk of pregnancy-induced hypertension in young recipients of donated oocytes. Fertil Steril. 2007 Apr;87(4):776-81. Epub 2007 Jan 29.</citation>
    <PMID>17258714</PMID>
  </reference>
  <reference>
    <citation>Klatsky PC, Delaney SS, Caughey AB, Tran ND, Schattman GL, Rosenwaks Z. The role of embryonic origin in preeclampsia: a comparison of autologous in vitro fertilization and ovum donor pregnancies. Obstet Gynecol. 2010 Dec;116(6):1387-92. doi: 10.1097/AOG.0b013e3181fb8e59.</citation>
    <PMID>21099607</PMID>
  </reference>
  <reference>
    <citation>Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006 Sep 7;355(10):992-1005. Erratum in: N Engl J Med. 2006 Oct 26;355(17):1840.</citation>
    <PMID>16957146</PMID>
  </reference>
  <reference>
    <citation>Le Ray C, Scherier S, Anselem O, Marszalek A, Tsatsaris V, Cabrol D, Goffinet F. Association between oocyte donation and maternal and perinatal outcomes in women aged 43 years or older. Hum Reprod. 2012 Mar;27(3):896-901. doi: 10.1093/humrep/der469. Epub 2012 Jan 16.</citation>
    <PMID>22252087</PMID>
  </reference>
  <reference>
    <citation>Lambers MJ, Groeneveld E, Hoozemans DA, Schats R, Homburg R, Lambalk CB, Hompes PG. Lower incidence of hypertensive complications during pregnancy in patients treated with low-dose aspirin during in vitro fertilization and early pregnancy. Hum Reprod. 2009 Oct;24(10):2447-50. doi: 10.1093/humrep/dep245. Epub 2009 Jul 16.</citation>
    <PMID>19608566</PMID>
  </reference>
  <reference>
    <citation>Nicolaides KH. A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment. Prenat Diagn. 2011 Jan;31(1):3-6. doi: 10.1002/pd.2685.</citation>
    <PMID>21210474</PMID>
  </reference>
  <reference>
    <citation>Pecks U, Maass N, Neulen J. Oocyte donation: a risk factor for pregnancy-induced hypertension: a meta-analysis and case series. Dtsch Arztebl Int. 2011 Jan;108(3):23-31. doi: 10.3238/arztebl.2011.0023. Epub 2011 Jan 21.</citation>
    <PMID>21285999</PMID>
  </reference>
  <reference>
    <citation>Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks. Ultrasound Obstet Gynecol. 2010 Jun;35(6):662-70. doi: 10.1002/uog.7628.</citation>
    <PMID>20232288</PMID>
  </reference>
  <reference>
    <citation>Ruano R, Fontes RS, Zugaib M. Prevention of preeclampsia with low-dose aspirin -- a systematic review and meta-analysis of the main randomized controlled trials. Clinics (Sao Paulo). 2005 Oct;60(5):407-14. Epub 2005 Oct 24. Review.</citation>
    <PMID>16254678</PMID>
  </reference>
  <reference>
    <citation>Salha O, Sharma V, Dada T, Nugent D, Rutherford AJ, Tomlinson AJ, Philips S, Allgar V, Walker JJ. The influence of donated gametes on the incidence of hypertensive disorders of pregnancy. Hum Reprod. 1999 Sep;14(9):2268-73.</citation>
    <PMID>10469693</PMID>
  </reference>
  <reference>
    <citation>Simhan HN, Caritis SN. Prevention of preterm delivery. N Engl J Med. 2007 Aug 2;357(5):477-87. Review.</citation>
    <PMID>17671256</PMID>
  </reference>
  <reference>
    <citation>Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002 Apr;87(4):1762-7.</citation>
    <PMID>11932314</PMID>
  </reference>
  <reference>
    <citation>Söderström-Anttila V. Pregnancy and child outcome after oocyte donation. Hum Reprod Update. 2001 Jan-Feb;7(1):28-32. Review.</citation>
    <PMID>11212070</PMID>
  </reference>
  <reference>
    <citation>Söderström-Anttila V, Tiitinen A, Foudila T, Hovatta O. Obstetric and perinatal outcome after oocyte donation: comparison with in-vitro fertilization pregnancies. Hum Reprod. 1998 Feb;13(2):483-90.</citation>
    <PMID>9557862</PMID>
  </reference>
  <reference>
    <citation>Groeneveld E, Lambers MJ, Lambalk CB, Broeze KA, Haapsamo M, de Sutter P, Schoot BC, Schats R, Mol BW, Hompes PG. Preconceptional low-dose aspirin for the prevention of hypertensive pregnancy complications and preterm delivery after IVF: a meta-analysis with individual patient data. Hum Reprod. 2013 Jun;28(6):1480-8. doi: 10.1093/humrep/det022. Epub 2013 Mar 25.</citation>
    <PMID>23528915</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2013</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>See incidence of Pre-Eclampsia in acetylsalicylic acid group</keyword>
  <keyword>See incidence of Pre-Eclampsia in placebo group</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

